Skip to content
Screener

Stereotaxis STXS EPS (Diluted)

EPS (Diluted) at other companies

Abbott logo
AbbottABT
$0.53-47.5%
Boston Scientific logo
Boston ScientificBSX
$0.61+15.1%
Medtronic logo
MedtronicMDT
$0.97+18.3%
Microbot Medical logo
Microbot MedicalMBOT
-$0.08+20.0%
Stryker logo
StrykerSYK
$3.30+44.1%
ITG
Integer HoldingsITGR
$0.48+173%

Other financials

Income statement

See full
Revenue$7.7M-12.8%
Gross profit$4.5M-2.0%
Operating income-$4.6M-14.9%
Net income-$4.5M-16.8%

Balance sheet

See full
Cash & equivalents$10.5M+50.6%
Total debt$5.2M-9.7%
Total equity$12.2M+741%
Total assets$55.6M+35.0%

Cash flow

See full
Operating cash flow-$3.7M+1.6%
CapEx$64.0K
Free cash flow-$3.7M

Valuation

See full
Market cap$145.29M-44.2%
Enterprise value$139.98M-45.9%
P/S4.8×-3.3×

Profitability

See full
Gross margin55.6%+5.4pp
Operating margin-75.7%+0.6pp
Net margin-74.2%+0.8pp
FCF margin-51.6%

Returns & leverage

See full
Return on equity-325.9%-31.2pp
Debt / equity0.4×-3.5×
Current ratio1.4×+0.4×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Stereotaxis’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001493152-26-037357
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cumulative dividend on convertible preferred stock(314)(318)(625)(632)
Net loss attributable to common stockholders$(4,782)$(4,144)$(10,954)$(10,281)
Net loss per share attributable to common stockholders:
Basic$(0.05)(0.05)$(0.11)$(0.12)
Diluted$(0.05)(0.05)$(0.11)$(0.12)
Weighted average number of common shares and equivalents:
Basic100,031,76087,952,08699,496,94287,861,231
Diluted100,031,76087,952,08699,496,94287,861,231

Item 1. Consolidated Financial Statements (unaudited) CONSOLIDATED

FAQ

What is Stereotaxis's EPS (diluted)?
Stereotaxis (STXS) reported EPS (diluted) of -$0.05 in Q2 2026.
How has Stereotaxis's EPS (diluted) changed year-over-year?
Stereotaxis's EPS (diluted) decreased by 0.0% year-over-year, from -$0.05 to -$0.05.
What is the long-term trend for Stereotaxis's EPS (diluted)?
Over 4 years (2021 to 2025), Stereotaxis's EPS (diluted) has grown at a 11.8% compound annual growth rate (CAGR), from -$0.16 to -$0.25.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Stereotaxis's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude